--Data supports MYCAPSSA® as non-inferior to long-actinginjectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly ...

NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved ...

Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too ...

Mycapssa is an oral somatostatin analogue. Mycapssa® (octreotide delayed-release capsules; Chiasma) is now available for the long-term maintenance treatment of adult patients with acromegaly who have ...

Amryt Announces Positive Long-TermSafety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patientswho have responded to and tolerated ...

Mycapssa (octreotide) is a brand-name drug that’s prescribed for certain adults with acromegaly. Mycapssa comes as a delayed-release oral capsule that’s typically taken twice per day. Octreotide is ...

Nearly four years ago, the FDA left for dead Chiasma's pill for abnormal limb and organ growth based on concerns over the design of a late-stage pivotal trial. But now that Chiasma has picked itself ...

DUBLIN, Ireland, and Boston MA, December 5, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for ...

DUBLIN, Ireland, and Boston MA, September 1 6 , 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments ...

The FDA has approved Mycapssa® (octreotide; Chiasma) capsules for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide ...

--Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs-- Raj Kannan, Chief Executive Officer ...

NEEDHAM, Mass., March 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology ...